Maggioni F, De Boni A, Rossi P, Villacara A, Zanchin G
Istituto di Clinica delle Malattie Nervose e Mentali, Università di Padova, Italy.
Ital J Neurol Sci. 1995 Oct;16(7):459-65. doi: 10.1007/BF02229323.
We assessed the attack drugs taken by 200 migraine without aura patients (International Headache Society criteria, 1988) between 1989 and 1991. A detailed pharmacological history regarding the acute attack therapy adopted up until our initial visit was gathered, including the type of drug used, dosage, administration route, the time of starting therapy, treatment efficacy, and the frequency and types of undesirable effects, all of which were subsequently compared with the guidelines (1993) of the Italian Society for the Study of Headache (SISC). The most commonly used are non steroidal anti-inflammatory drugs (NSAIDs). We observed a similar high frequency in the use of combinations, particularly prophyphenazone and barbituric acid. The pirazolones, such as noramidopyrine and prophyphenazone, are also widely used as single agents, even though they are not considered by the guidelines. Our study underlines the fact that current drug use differs in several respects from the guidelines.
我们评估了1989年至1991年间200例无先兆偏头痛患者（依据1988年国际头痛协会标准）服用的缓解药物。收集了关于直至我们初次就诊时所采用的急性发作治疗的详细用药史，包括所用药物的类型、剂量、给药途径、开始治疗的时间、治疗效果以及不良反应的频率和类型，所有这些随后都与意大利头痛研究协会（SISC）1993年的指南进行了比较。最常用的是非甾体抗炎药（NSAIDs）。我们观察到联合用药的频率也很高，尤其是安替比林和巴比妥酸。吡唑酮类药物，如氨基比林和安替比林，即使未被指南认可，也广泛用作单一药物。我们的研究强调了当前药物使用在几个方面与指南不同这一事实。
